Dose optimisation and dose intensification in malignant lymphoma.
Linch
D C
DC
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D006402:Hematologic Diseases / Q000139:chemically induced / Q000188:drug therapy; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*
D016298:Hematopoietic Cell Growth Factors